Altimmune, a clinical-stage biopharmaceutical company in Gaithersburg, Maryland, develops peptide-based therapeutics for obesity and liver diseases, including the lead candidate pemvidutide. The company has completed Phase II trials for both pemvidutide and HepTcell, targeting metabolic dysfunction and hepatitis B.
Catherine A Sohn bought 1,000 shares of ALT on 17 March at $5.78 per share, worth a total of $6K. They now own 1,000 ALT shares.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
